All In Biotech

Drug Trial Radar · NCT06673667

First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants

A Phase 1, Randomized, Placebo-Controlled, First-in-Human, Single and Multiple Ascending Dose Study Designed to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered KT-621 in Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 118 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

118

Actual

Start

Oct 22, 2024

Primary completion

Apr 23, 2025

Study completion Apr 23, 2025

Sponsor

Lead sponsor
Kymera Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 19 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a first-in-human study to evaluate safety, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-621 in healthy male and female adult participants.

Conditions

  • Healthy Participants Study

Interventions

  • KT-621Drug

    Oral drug

  • PlaceboDrug

    Oral drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse eventsTime frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)
  2. Treatment-emergent potentially clinically-significant abnormalities in safety laboratory parameters: hematologyTime frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)
  3. Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: serum chemistryTime frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)
  4. Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: coagulationTime frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)
  5. Treatment-emergent potentially clinically significant abnormalities in electrocardiogram values: QTcF (milliseconds)Time frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)
  6. Treatment-emergent potentially clinically significant abnormalities in vital signs: heart rate (beats per minute)Time frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)
  7. Treatment-emergent potentially clinically significant abnormalities in vital signs: blood pressure (mmHg)Time frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)
  8. Treatment-emergent potentially clinically significant abnormalities in vital signs: respiratory rate (breaths per minute)Time frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)
  9. Treatment-emergent potentially clinically significant abnormalities in vital signs: temperature (degrees Celsius)Time frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Celerion

    Phoenix, Arizona

  • Celerion

    Lincoln, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.